Skip to main content
Premium Trial:

Request an Annual Quote

Synthego Raises $100M in Series D Financing Round

NEW YORK – Genome engineering firm Synthego said on Wednesday that it has raised $100 million in a Series D financing round.

The round was led by new investor Wellington Management, as well as by RA Capital Management and 8VC. Founders Fund, Menlo Ventures, and Intel Capital also participated, the company said, noting that this new round brings its total private funding raised to more than $250 million.

Synthego said it will use the proceeds from the financing to expand the capabilities of its proprietary platforms, which are designed to produce standardized CRISPR reagents and engineered cells to conduct basic research, target identification, and clinical trials.

The company also appointed Robert Deans as CSO and John Tan as chief operating officer.

"Working with dozens of world-class academic institutions and top Fortune 500 biopharmaceutical companies that have contributed to our progress in transforming the life sciences, we are pleased to have such strong investor support as we continue to execute on our vision and platform technologies, which enable scientists to discover and develop new therapies for serious diseases," Synthego Cofounder and CEO Paul Dabrowski said in a statement.